학술논문


EBSCO Discovery Service
발행년
-
(예 : 2010-2015)
전자자료 공정이용 안내

우리 대학 도서관에서 구독·제공하는 모든 전자자료(데이터베이스, 전자저널, 전자책 등)는 국내외 저작권법과 출판사와의 라이선스 계약에 따라 엄격하게 보호를 받고 있습니다.
전자자료의 비정상적 이용은 출판사로부터의 경고, 서비스 차단, 손해배상 청구 등 학교 전체에 심각한 불이익을 초래할 수 있으므로, 아래의 공정이용 지침을 반드시 준수해 주시기 바랍니다.

공정이용 지침
  • 전자자료는 개인의 학습·교육·연구 목적의 비영리적 사용에 한하여 이용할 수 있습니다.
  • 합리적인 수준의 다운로드 및 출력만 허용됩니다. (일반적으로 동일 PC에서 동일 출판사의 논문을 1일 30건 이하 다운로드할 것을 권장하며, 출판사별 기준에 따라 다를 수 있습니다.)
  • 출판사에서 제공한 논문의 URL을 수업 관련 웹사이트에 게재할 수 있으나, 출판사 원문 파일 자체를 복제·배포해서는 안 됩니다.
  • 본인의 ID/PW를 타인에게 제공하지 말고, 도용되지 않도록 철저히 관리해 주시기 바랍니다.
불공정 이용 사례
  • 전자적·기계적 수단(다운로딩 프로그램, 웹 크롤러, 로봇, 매크로, RPA 등)을 이용한 대량 다운로드
  • 동일 컴퓨터 또는 동일 IP에서 단시간 내 다수의 원문을 집중적으로 다운로드하거나, 전권(whole issue) 다운로드
  • 저장·출력한 자료를 타인에게 배포하거나 개인 블로그·웹하드 등에 업로드
  • 상업적·영리적 목적으로 자료를 전송·복제·활용
  • ID/PW를 타인에게 양도하거나 타인 계정을 도용하여 이용
  • EndNote, Mendeley 등 서지관리 프로그램의 Find Full Text 기능을 이용한 대량 다운로드
  • 출판사 콘텐츠를 생성형 AI 시스템에서 활용하는 행위(업로드, 개발, 학습, 프로그래밍, 개선 또는 강화 등)
위반 시 제재
  • 출판사에 의한 해당 IP 또는 기관 전체 접속 차단
  • 출판사 배상 요구 시 위반자 개인이 배상 책임 부담
'학술논문' 에서 검색결과 566건 | 목록 1~20
Commentary on: “Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial.” Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR, CA184-043 Investigators. Departments of Urology and Immunology and Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN, USA, Electronic address: kwon.eugene@mayo.edu; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Brady Urological Institute, Baltimore, MD, USA; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA; Institut Gustave Roussy, University of Paris-Sud, Villejuif, France; Institut Gustave Roussy, Villejuif, France; VU University Medical Centre, Amsterdam, Netherlands; Vienna General Hospital, Medical University Vienna, Vienna, Austria; Institut Bergonié, Bordeaux, France; CHU Caremeau, Nimes, France; Centro Médico Austral, Buenos Aires, Argentina; Centre Jean Perrin, Clermont-Ferrand, France; St John of God Hospital, Subiaco, WA, Australia; University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy; Hospital de Caridade de Ijuí, Ijuí, Brazil; Nottingham University Hospital, Nottingham, UK; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; Netherlands Cancer Institute and Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Institute of Oncology Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania; Hospital Británico de Buenos Aires, Buenos Aires, Argentina; Herlev Hospital, Herlev, Denmark; Odense University Hospital, Odense, Denmark; University of Texas MD Anderson Cancer Center, Houston, TX, USA; Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA; Bristol-Myers Squibb, Wallingford, CT, USA; Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands.
Academic Journal
In Urologic Oncology: Seminars and Original Investigations May 2016 34(5):249-250
Academic Journal
Alonso S; Department of Biostatistics, Clinical Epidemiology, Public Health and Innovation in Methodology (BESPIM), CHU Nîmes, Univ Montpellier, Nîmes, France.; Kabani S; Department of Biostatistics, Clinical Epidemiology, Public Health and Innovation in Methodology (BESPIM), CHU Nîmes, Univ Montpellier, Nîmes, France.; Fabbro-Peray P; Department of Biostatistics, Clinical Epidemiology, Public Health and Innovation in Methodology (BESPIM), CHU Nîmes, Univ Montpellier, Nîmes, France.; Houédé N; Institut de Cancérologie du Gard, CHU Nîmes, Univ Montpellier, Nîmes, France.; INSERM U1194, Montpellier Cancer Research Institute, Montpellier, France.; Duwig L; Department of Medical Oncology CHU Nîmes, Univ Montpellier, Place du Professeur Debré, 30029, Nîmes Cedex 09, France. luc.duwig@chu-nimes.fr.
Publisher: BioMed Central Country of Publication: England NLM ID: 101627676 Publication Model: Electronic Cited Medium: Internet ISSN: 2050-7283 (Electronic) Linking ISSN: 20507283 NLM ISO Abbreviation: BMC Psychol Subsets: MEDLINE
Academic Journal
In Progrès en Urologie November 2019 29(15):922-928
Academic Journal
In Progrès en Urologie June 2019 29 Supplement 1:S42-S50
Academic Journal
Houédé N; Department of Oncology, CHU Nîmes, Nîmes, France.; INSERM U1194, Montpellier University, Montpellier, France.; Chevallier T; CHU Nîmes, Department of Biostatistics, Epidemiology, Public Health and Innovation in Methodology, Nîmes, France.; UMR 1302, Desbrest Institute of Epidemiology and Public Health, INSERM, Montpellier University, Montpellier, France.; Audenet F; Department of Urology, Georges Pompidou European Hospital, AP-HP Centre, Paris Cité University, Paris, France.; Thibault C; Department of Medical Oncology, Georges Pompidou European Hospital, AP-HP, Paris Cité University, Paris, France.; Institut Du Cancer Paris CARPEM, AP-HP Centre, Paris Cité University, Paris, France.; Neuzillet Y; Department of Urology, Foch Hospital, Paris-Saclay University, Paris, France.; Abraham C; Department of Oncology, Foch Hospital, Paris, France.; Masson-Lecomte A; Paris Cité University, U976 HIPI, Saint-Louis Research Institute, Paris, France.; Urology Department, APHP, Saint Louis Hospital, Paris, France.; Gauthier H; Department of Medical Oncology, Saint Louis Hospital, Paris, France.; Gravis G; Department of Medical Oncology, Paoli-Calmettes Institute, Aix Marseille University, INSERM, CNRS, CRCM, Immunity and Cancer Team, Marseille, France.; Pignot G; Department of Surgical Oncology, Paoli-Calmettes Institute, Marseille, France.; Tartas S; Department of Medical Oncology, IMMUCARE, Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices de Lyon (IC-HCL), Pierre-Bénite, France.; Ruffion A; Urology Department, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon Cancer Innovation Center (EA 3738 CICLY), Lyon Sud Medical School, University of Lyon 1, Lyon, France.; Pouessel D; Department of Medical Oncology, Oncopole Claudius Regaud - IUCT-O, Toulouse, France.; Toulouse Cancer Research Centre, Toulouse, France.; Roumiguié M; Department of Urology, CHU Toulouse, Toulouse III University, Toulouse, France.; Laguerre B; Department of Medical Oncology, Eugene Marquis Cancer Center, Rennes, France.; Bensalah K; Department of Urology, Rennes University, Rennes, France.; Xylinas E; Department of Urology, Bichat Claude-Bernard Hospital, AP-HP Nord, Paris Cité University, Paris, France.; Jaffrelot L; Department of Oncology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.; Droupy S; Department of Urology, CHU Nîmes, Montpellier University, Nîmes, France.; Luquiens G; CHU Nîmes, Department of Biostatistics, Epidemiology, Public Health and Innovation in Methodology, Nîmes, France.; Rouprêt M; Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitié-Salpêtrière Hospital, Paris, France.
Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
검색 결과 제한하기
제한된 항목
[검색어] Houédé N
발행연도 제한
-
학술DB(Database Provider)
저널명(출판물, Title)
출판사(Publisher)
자료유형(Source Type)
주제어
언어